Trinity Biotech Plc (TRIB)

0.92
0.03 3.66
NASDAQ : Health Technology
Prev Close 0.89
Open 0.88
Day Low/High 0.86 / 0.99
52 Wk Low/High 0.63 / 3.36
Volume 76.59K
Avg Volume 106.00K
Exchange NASDAQ
Shares Outstanding 24.04M
Market Cap 22.84M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trinity Biotech Announces Results For Fiscal Year 2012

Trinity Biotech Announces Results For Fiscal Year 2012

Profit After Tax Increases by 11% to $17.3m

Trinity Biotech Plc To Announce Fourth Quarter And Fiscal Year 2012 Financial Results

Trinity Biotech Plc To Announce Fourth Quarter And Fiscal Year 2012 Financial Results

Conference Call Scheduled for March 5, 2013 at 11:00 am EASTERN

Trinity Biotech Plc To Announce Third Quarter Fiscal Year 2012 Financial Results

Trinity Biotech Plc To Announce Third Quarter Fiscal Year 2012 Financial Results

Conference Call Scheduled for October 18, 2012 at 11:00 am EASTERN

Still Pulling In the Buyers

Still Pulling In the Buyers

These stocks all bear watching, as they saw heavy upside volume even amid Tuesday's downturn.

Trinity Biotech PLC Stock Upgraded (TRIB)

Trinity Biotech PLC Stock Upgraded (TRIB)

Trinity Biotech (Nasdaq:TRIB) has been upgraded by TheStreet Ratings from a hold to buy.

Wall St. Confidential: Cramer Says There's No Way Out for NY Times

The situation is just plain awful, says Jim.

Today's Health Winners and Losers

Today's Health Winners and Losers

Urologix shares jump after the FDA clears its treatment of benign prostatic hyperplasia.

FDA Ruling Boosts Trinity Biotech

FDA Ruling Boosts Trinity Biotech

U.S. regulators approve expanded use of the Irish biotech company's HIV test.

Trinity Biotech Surges Again

Investors follow through on Monday's rally triggered by FDA approval of HIV testing device.

Trinity Biotech Soars on FDA OK

Trinity Biotech Soars on FDA OK

Its 10-minute AIDS test is cleared for U.S. marketing.

TheStreet Quant Rating: D (Sell)